Outcomes in COVID-19 rhu-pGSN studies

0 0.5 1 1.5+ All studies -3% 1 61 Improvement, Studies, Patients Relative Risk Mortality -3% 1 61 Ventilation 48% 1 61 RCTs -3% 1 61 Late -3% 1 61 Rhu-pGSN for COVID-19 c19early.org November 2025 Favorsrhu-pGSN Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] death 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Effect extraction pre-specified(most serious outcome) Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) 48% 0.52 [0.14-1.88] 3/30 6/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.32 Late treatment 48% 0.52 [0.14-1.88] 3/30 6/31 48% lower risk All studies 48% 0.52 [0.14-1.88] 3/30 6/31 48% lower risk 1 rhu-pGSN COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.32 Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] death 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Effect extraction pre-specified(most serious outcome) Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] death 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Effect extraction pre-specified(most serious outcome) Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] death 2/30 2/31 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Late treatment -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk All studies -3% 1.03 [0.16-6.87] 2/30 2/31 3% higher risk 1 rhu-pGSN COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.98 Effect extraction pre-specified(most serious outcome) Favors rhu-pGSN Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ DiNubile (DB RCT) -3% 1.03 [0.16-6.87] death 2/30 2/31 Improvement, RR [CI] Treatment Control DiNubile (DB RCT) 48% 0.52 [0.14-1.88] ventilation 3/30 6/31 DiNubile (DB RCT) -29% 1.29 [0.38-4.35] progression 5/30 4/31 Rhu-pGSN COVID-19 outcomes c19early.org November 2025 Favors rhu-pGSN Favors control